ClinicalTrials.gg
CompletedNCT00674752Updated Feb 2, 2021

A Polysomnographic Study Of Single-Dose Gabapentin In Transient Insomnia

A Phase 3 interventional study of Gabapentin and Gabapentin in Transient Insomnia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-02.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
377
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders — none open to participants now, none under way, none of them phase 3. Gabapentin · Sleep Initiation and Maintenance Disorders.

Enrollment
6th of 14
377 · median 283
Started
2006
with 1 other
Phase 3
9 of 14
none open now
Registered
8th of 14
by date
Lead sponsor
9 of 14
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders, this one is the 6th largest by enrollment, is one of 2 that started in 2006, is one of 9 in phase 3, and was the 8th registered.

Sleep Initiation and Maintenance Disorders

2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

None of the 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders is open now. The open studies under Sleep Initiation and Maintenance Disorders, anywhere →

Where they have run

About gabapentin

Gabapentin: first FDA approval 1993 (NEURONTIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders as a file.
02

Study summary

The purpose of this study is to assess the effect of gabapentin on polysomnographic assessments in transient insomnia induced by a sleep phase advance.

03

Conditions studied

  • Transient Insomnia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged >/= 18 years who reported occasional sleeplessness in the month prior to screening
  • Females of using medically-acceptable method of >/= 1 month prior to screening

Exclusion criteria

Exclusion Criteria:

  • Current or recent history (within 2 years) of sleep disorder (excessive snoring, obstructive sleep apnea, chronic painful condition)
  • Currently taking or expected to take any of the following during the trial: amphetamines, benzodiazepines, cocaine, marijuana, methaqualone, methadone, opiates, propoxyphene, barbituates, and phencyclidine
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
377 participants (actual)

Study arms

  • Experimental
    A

    Drug: Gabapentin

  • Experimental
    B

    Drug: Gabapentin

  • Placebo comparator
    C

    Drug: Placebo

Interventions

  • Gabapentin 250 mg oral capsule 30 minutes prior to bedtime

  • Gabapentin 500 mg oral capsule 30 minutes prior to bedtime

  • DrugPlacebo

    Matched placebo oral capsule 30 minutes prior to bedtime

06

What researchers measure

Primary outcomes

  1. Wake after sleep onset as measured by polysomnography (PSG)

    Time frame: Hour +8

Secondary outcomes

  1. PSG Latency to Persistent Sleep

    Time frame: Hour +8

  2. PSG Wake Time During Sleep

    Time frame: Hour +8

  3. PSG WASO

    Time frame: Hour +8

  4. PSG Sleep Onset Latency

    Time frame: Hour +8

  5. Vital signs

    Time frame: Hour +8

  6. Karolinska Sleep Diary-Sleep (KSD) Quality Index

    Time frame: Hour +8

  7. KSD individual scores

    Time frame: Hour +8

  8. PSG NA

    Time frame: Hour +8

  9. Adverse events

    Time frame: Hour +13

  10. PSG Total wake time plus Stage 1 sleep

    Time frame: Hour +8

  11. PSG TST

    Time frame: Hour +8

  12. PSG Sleep Efficiency

    Time frame: Hour +8

  13. PSG Percent of Stages 1, 2, 3, 4 and REM sleep

    Time frame: Hour +8

  14. PSG Percent slow wave sleep (Stages 3&4 combined)

    Time frame: Hour +8

  15. subjective Sleep Latency

    Time frame: Hour +8

  16. subjective Number of Awakenings (NA)

    Time frame: Hour +8

  17. subjective Wake After Sleep Onset (WASO)

    Time frame: Hour +8

  18. subjective Total Sleep Time (TST)

    Time frame: Hour +8

  19. subjective Assessment of Sleep Refreshment

    Time frame: Hour +8

  20. subjective Assessment of Sleep Quality

    Time frame: Hour +8

07

Study locations

4 sites
  • Pfizer Investigational Site
    Miami, Florida 33143, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30342, United States
  • Pfizer Investigational Site
    Overland Park, Kansas 66212, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio 45227, United States
08

References and documents

Publications

  • Rosenberg RP, Hull SG, Lankford DA, Mayleben DW, Seiden DJ, Furey SA, Jayawardena S, Roth T. A randomized, double-blind, single-dose, placebo-controlled, multicenter, polysomnographic study of gabapentin in transient insomnia induced by sleep phase advance. J Clin Sleep Med. 2014 Oct 15;10(10):1093-100. doi: 10.5664/jcsm.4108. PubMed 25317090 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2006 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2008
First posted
May 8, 2008
Start
Mar 2006
CompletionActual
Aug 2006
Last update
Feb 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00674752
Responsible party
Sponsor
First posted
May 8, 2008
Start date
Mar 2006
Completion
Aug 2006
Last update
Feb 2, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gabapentin

Start the discussion